Dr Zhang is responsible for the overall management and operation of our Group, R&D and corporate strategies. He earned his Ph.D. from Purdue University under the mentorship of Nobel Chemistry Prize Winner Professor Ei-ichi Negishi. He has over 30 years of experience in the pharmaceutical industry, and has served multiple roles at Eli Lilly and Company, including the founding managing director of the China R&D center and Vice President of Global External R&D for Asia. He was a recipient of Lilly’s “Chairman’s Ovation Award” for his contribution to R&D productivity. He has also served as Chairman of BayHelix Group.

Dr. Zhao is responsible for novel target discovery, biomarker strategy development, and PK/PD-driven translational research. He received his Ph.D. from the University of Florida and completed his postdoctoral training at the University of Texas Medical School. Prior to joining Tyligand Bioscience, he spent more than 20 years at Eli Lilly and Company, where he advanced multiple clinical assets across cancer cell signaling, metabolism, and immuno-oncology.

Mrs. Li is responsible for clinical strategy and development. She received bachelor degree at Tongji Medical College, Huazhong University of Science and Technology and master degree at Shanghai Medical College, Fudan University. She has extensive experience in the clinical development of innovative drugs. She has previously worked at Sanofi, HUTCHMED, and Transcenta, where she and her team successfully brought several drugs to market in China and into global development. Her work experience covers the different stages of clinical development in support of making innovative medicines available to patients globally.

Dr. Xiao is responsible for business development, investor relations and corporate strategy. He obtained a master’s degree in management and a Ph.D. in genetics and genomics from the University of Florida. He has extensive experience in the pharmaceutical industry, having served as a scientist at China Innovation Center of Roche, manager at Genor Biopharma and 3SBIO Inc., and vice president at Shanghai Pharmaceuticals (Hong Kong) Investment Co., Ltd.